Source: GlobeNewswire

Press Release: Myovant Sciences : Myovant Sciences and Evidation Health Announce Partnership and Launch Digital Insights Study on Menstruation

BASEL, Switzerland and SAN MATEO, Calif., July 10, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, and Evidation Health, a health and measurement company that helps life sciences and healthcare companies understand how everyday behavior and health interact, today announced a collaboration to conduct a digital study on the prevalence and impact of menstrual symptoms experienced by women in the U.S., as well as an evaluation of the education and attitudes of women and men regarding menstruation.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Lynn Seely's photo - President & CEO of Myovant Sciences

President & CEO

Lynn Seely

CEO Approval Rating

89/100

Myovant Sciences is a biopharmaceutical company that develops and commercializes therapeutics for the treatment of fibroids and prostate cancer. Read more